Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter, Open-label, Randomized Controlled Study to Evaluate Safety and Effectiveness of Endoscopic Hemostatic Powder, 'Nexpowder' for Hemostatic Treatments of Lower Gastrointestinal Bleeding After Colon Polypectomy

NCT05884931 is registered in ClinicalTrials.gov with Next Biomedical Co., Ltd. as lead sponsor.

NCT NCT05884931
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05884931 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter, Open-label, Randomized Controlled Study to Evaluate Safety and Effectiveness of Endoscopic Hemostatic Powder, 'Nexpowder' for Hemostatic Treatments of Lower Gastrointestinal Bleeding After Colon Polypectomy
Lead sponsor
Next Biomedical Co., Ltd.
Phase
Not applicable
Overall status
Completed
Start date
October 18, 2022
Completion date
December 29, 2023
Enrollment
66 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal bleeding